Paul Hastings LLP advised Orchestra BioMed on the deal.
Orchestra BioMed announced a strategic collaboration with Medtronic to develop Orchestra BioMed’s BackBeat Cardiac Neuromodulation Therapy™ (CNT™) as a potential treatment for hypertension in patients who are indicated for a cardiac pacemaker.
Orchestra BioMed is a a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships.
The Paul Hastings team was led by M&A/Emerging Growth Companies partner Sam Waxman (Picture), and included partners Yariv Katz, Lucas Rachuba, and Todd Schneider; of counsels Keith Pisani and Amy Lawrence; and associates Jordan Goldman, Vinnie Buehler, Anna Hardcastle, Tianzi Wu, Nicolette Ursini and Shai Marshall.
Involved fees earner: Vinnie Buehler – Paul Hastings LLP; Jordan Goldman – Paul Hastings LLP; Anna Hardcastle – Paul Hastings LLP; Yariv Katz – Paul Hastings LLP; Amy Lawrence – Paul Hastings LLP; Shai Marshall – Paul Hastings LLP; Keith Pisani – Paul Hastings LLP; Lucas Rachuba – Paul Hastings LLP; Todd Schneider – Paul Hastings LLP; Nicolette Ursini – Paul Hastings LLP; Samuel Waxman – Paul Hastings LLP; Tianzi Wu – Paul Hastings LLP;
Law Firms: Paul Hastings LLP;
Clients: Orchestra BioMed;
